BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

MIMETAS And Galapagos NV (GLPG.BR) To Develop Human Disease Models On-A-Chip


1/13/2014 8:56:53 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Leiden, the Netherlands, January 13, 2014 / B3C newswire / - MIMETAS and Galapagos (Euronext: GLPG) have entered into a research collaboration on the development of organ-on-a-chip-based human disease models for new medicine development.

The companies will collaborate to develop miniaturized 3D cell culture models that mimic specific aspects of human diseases. These models will be applied to the identification and improvement of novel compounds. Dr. Richard Janssen, Senior Director of Target Discovery at Galapagos, states: “The MIMETAS platform is the first to combine organ-on-a-chip technology with our high throughput screening of primary human cells. As we see it, OrganoPlates™ make 3D culture as straightforward as traditional cell culture.”

Dr. Jos Joore, MIMETAS’ CBO underscores this notion: “This agreement is a crucial step forward for MIMETAS and for the organ-on-a-chip field in general. Galapagos sets an example as one of the first drug discovery companies worldwide to implement innovative organ-on-a-chip technologies. This collaboration helps us to further validate our technology, by enabling development of unique novel compounds with unique human disease models.”

Financial and technological details of the agreement have not been disclosed.

About MIMETAS

MIMETAS develops organ-on-a-chip technology for testing of new medicines. Its unique microfluidic technology enables testing of new medicines in high-throughput on miniaturized organ models. These models have better predictivity compared to laboratory animals and conventional cell culture models. The MIMETAS OrganoPlate™ platform allows 3D cell culture under continuous perfusion and for membrane-free co-culture, boundary and gradient formation. MIMETAS develops and validates customized disease, toxicology and transport models and ultimately will make its technology available for personalized therapy selection.

About Galapagos

Galapagos (Euronext: GLPG; OTC: GLPYY) is specialized in novel modes-of-action, with a large pipeline comprising of six Phase 2 studies (three led by GSK), one Phase 1 study, five pre-clinical, and 20 discovery small-molecule and antibody programs in cystic fibrosis, inflammation, antibiotics, metabolic disease, and other indications.

The Galapagos Group, including fee-for-service companies BioFocus, Argenta and Fidelta , has around 800 employees and operates facilities in five countries, with global headquarters in Mechelen, Belgium.

Contact Galapagos NV
Richard Janssen, Sr Director Target Discovery
Richard.janssen@glpg.com
+31 71 7506 700
Contact MIMETAS BV
Jos Joore, Chief Business Officer
j.joore@mimetas.com
+31 651 696 884

Help employers find you! Check out all the jobs and post your resume.


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES